Drug Profile
Research programme: oncology and infectious diseases companion diagnostic - Biocartis/Debiopharm
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biocartis; Debiopharm Group
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Diagnosis) in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in Infections(Diagnosis) in Switzerland
- 08 Apr 2010 Early research in Cancer (Diagnosis) in Switzerland (unspecified route)